164 related articles for article (PubMed ID: 35684298)
21. Syntheses, cholinesterases inhibition, and molecular docking studies of pyrido[2,3-b]pyrazine derivatives.
Hameed A; Zehra ST; Shah SJ; Khan KM; Alharthy RD; Furtmann N; Bajorath J; Tahir MN; Iqbal J
Chem Biol Drug Des; 2015 Nov; 86(5):1115-20. PubMed ID: 25951978
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and biological evaluation of indoloquinoline alkaloid cryptolepine and its bromo-derivative as dual cholinesterase inhibitors.
Nuthakki VK; Mudududdla R; Sharma A; Kumar A; Bharate SB
Bioorg Chem; 2019 Sep; 90():103062. PubMed ID: 31220673
[TBL] [Abstract][Full Text] [Related]
23. Identification of New Chromenone Derivatives as Cholinesterase Inhibitors and Molecular Docking Studies.
Iqbal J; Abbasi MSA; Zaib S; Afridi S; Furtmann N; Bajorath J; Langer P
Med Chem; 2018; 14(8):809-817. PubMed ID: 29473519
[TBL] [Abstract][Full Text] [Related]
24. In Silico Docking and In Vitro Approaches towards BACE1 and Cholinesterases Inhibitory Effect of Citrus Flavanones.
Lee S; Youn K; Lim G; Lee J; Jun M
Molecules; 2018 Jun; 23(7):. PubMed ID: 29932100
[TBL] [Abstract][Full Text] [Related]
25. Cholinesterase inhibitory activity of isoquinoline alkaloids from three Cryptocarya species (Lauraceae).
Wan Othman WNN; Liew SY; Khaw KY; Murugaiyah V; Litaudon M; Awang K
Bioorg Med Chem; 2016 Sep; 24(18):4464-4469. PubMed ID: 27492195
[TBL] [Abstract][Full Text] [Related]
26. Cholinesterases inhibition and molecular modeling studies of piperidyl-thienyl and 2-pyrazoline derivatives of chalcones.
Shah MS; Khan SU; Ejaz SA; Afridi S; Rizvi SUF; Najam-Ul-Haq M; Iqbal J
Biochem Biophys Res Commun; 2017 Jan; 482(4):615-624. PubMed ID: 27865835
[TBL] [Abstract][Full Text] [Related]
27. Structure Related Inhibition of Enzyme Systems in Cholinesterases and BACE1 In Vitro by Naturally Occurring Naphthopyrone and Its Glycosides Isolated from Cassia obtusifolia.
Shrestha S; Seong SH; Paudel P; Jung HA; Choi JS
Molecules; 2017 Dec; 23(1):. PubMed ID: 29283428
[No Abstract] [Full Text] [Related]
28. Synthesis, molecular docking and biological evaluation of N,N-disubstituted 2-aminothiazolines as a new class of butyrylcholinesterase and carboxylesterase inhibitors.
Makhaeva GF; Boltneva NP; Lushchekina SV; Serebryakova OG; Stupina TS; Terentiev AA; Serkov IV; Proshin AN; Bachurin SO; Richardson RJ
Bioorg Med Chem; 2016 Mar; 24(5):1050-62. PubMed ID: 26827140
[TBL] [Abstract][Full Text] [Related]
29. Synthesis, Characterization and Cholinesterase Inhibition Studies of New Arylidene Aminothiazolylethanone Derivatives.
Channar PA; Shah MS; Saeed A; Khan SU; Larik FA; Shabir G; Iqbal J
Med Chem; 2017; 13(7):648-653. PubMed ID: 28266279
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of Butyrylcholinesterase and Human Monoamine Oxidase-B by the Coumarin Glycyrol and Liquiritigenin Isolated from
Jeong GS; Kang MG; Lee JY; Lee SR; Park D; Cho M; Kim H
Molecules; 2020 Aug; 25(17):. PubMed ID: 32859055
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and cholinesterase inhibitory activity study of new piperidone grafted spiropyrrolidines.
Basiri A; Abd Razik BM; Ezzat MO; Kia Y; Kumar RS; Almansour AI; Arumugam N; Murugaiyah V
Bioorg Chem; 2017 Dec; 75():210-216. PubMed ID: 28987876
[TBL] [Abstract][Full Text] [Related]
32. Aromatic amino-acid residues at the active and peripheral anionic sites control the binding of E2020 (Aricept) to cholinesterases.
Saxena A; Fedorko JM; Vinayaka CR; Medhekar R; Radić Z; Taylor P; Lockridge O; Doctor BP
Eur J Biochem; 2003 Nov; 270(22):4447-58. PubMed ID: 14622273
[TBL] [Abstract][Full Text] [Related]
33. Structural modifications of 4-aryl-4-oxo-2-aminylbutanamides and their acetyl- and butyrylcholinesterase inhibitory activity. Investigation of AChE-ligand interactions by docking calculations and molecular dynamics simulations.
Vitorović-Todorović MD; Koukoulitsa C; Juranić IO; Mandić LM; Drakulić BJ
Eur J Med Chem; 2014 Jun; 81():158-75. PubMed ID: 24836068
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of cholinesterases by safranin O: Integration of inhibition kinetics with molecular docking simulations.
Onder S; Sari S; Tacal O
Arch Biochem Biophys; 2021 Feb; 698():108728. PubMed ID: 33345803
[TBL] [Abstract][Full Text] [Related]
35. Flavonols and 4-thioflavonols as potential acetylcholinesterase and butyrylcholinesterase inhibitors: Synthesis, structure-activity relationship and molecular docking studies.
Mughal EU; Sadiq A; Ashraf J; Zafar MN; Sumrra SH; Tariq R; Mumtaz A; Javid A; Khan BA; Ali A; Javed CO
Bioorg Chem; 2019 Oct; 91():103124. PubMed ID: 31319297
[TBL] [Abstract][Full Text] [Related]
36. Structural aspects of 4-aminoquinolines as reversible inhibitors of human acetylcholinesterase and butyrylcholinesterase.
Bosak A; Opsenica DM; Šinko G; Zlatar M; Kovarik Z
Chem Biol Interact; 2019 Aug; 308():101-109. PubMed ID: 31100281
[TBL] [Abstract][Full Text] [Related]
37. Computational exploration and experimental validation to identify a dual inhibitor of cholinesterase and amyloid-beta for the treatment of Alzheimer's disease.
Tripathi MK; Sharma P; Tripathi A; Tripathi PN; Srivastava P; Seth A; Shrivastava SK
J Comput Aided Mol Des; 2020 Sep; 34(9):983-1002. PubMed ID: 32488355
[TBL] [Abstract][Full Text] [Related]
38. Withanolides, a new class of natural cholinesterase inhibitors with calcium antagonistic properties.
Choudhary MI; Nawaz SA; ul-Haq Z; Lodhi MA; Ghayur MN; Jalil S; Riaz N; Yousuf S; Malik A; Gilani AH; ur-Rahman A
Biochem Biophys Res Commun; 2005 Aug; 334(1):276-87. PubMed ID: 16108094
[TBL] [Abstract][Full Text] [Related]
39. Differences in active-site gorge dimensions of cholinesterases revealed by binding of inhibitors to human butyrylcholinesterase.
Saxena A; Redman AM; Jiang X; Lockridge O; Doctor BP
Chem Biol Interact; 1999 May; 119-120():61-9. PubMed ID: 10421439
[TBL] [Abstract][Full Text] [Related]
40. In silico and in vitro anti-AChE activity investigations of constituents from Mytragyna speciosa for Alzheimer's disease treatment.
Innok W; Hiranrat A; Chana N; Rungrotmongkol T; Kongsune P
J Comput Aided Mol Des; 2021 Mar; 35(3):325-336. PubMed ID: 33439402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
